The locomotor-reducing effects of GABAergic drugs do not depend on the GABAA receptor.
The locomotion-reducing effect of the GABAB agonist baclofen was compared with that of the GABAA agonists, aminopropanesulfonic acid (APSA) and THIP. It was found that baclofen was more potent than the other drugs. After intraventricular injection, baclofen induced almost complete immobility, whereas APSA did not affect locomotor activity. THIP had an intermediate effect. The GABA transaminase inhibitor gamma-acetylenic GABA (GAG) provoked a dose-dependent reduction of locomotion. Neither the effects of THIP nor those of GAG could be blocked by concurrent administration of bicuculline. The antagonist itself did not affect locomotor activity. It is concluded that the GABAA receptor is not important for the locomotion-reducing effects of GABAergic drugs.
D000480:Alkynes; D000614:Aminocaproates / Q000494:pharmacology; D000818:Animals; D001418:Baclofen / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D007555:Isoxazoles / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000502:physiology; D013654:Taurine / Q000031:analogs & derivatives / Q000494:pharmacology
D000480:Alkynes; D000614:Aminocaproates; D007555:Isoxazoles; D011963:Receptors, GABA-A; D013654:Taurine; C013785:4-amino-5-hexynoic acid; C001355:tramiprosate; D001418:Baclofen; C015542:gaboxadol; D001640:Bicuculline